$MODD

Modular Medical (MODD) received a positive ISO 13485:2016 decision, a step toward certification. The company aims for a 2027 CE Mark submission for its Pivot tubeless patch pump under EU MDR. This milestone supports its EU launch plan, with certification and CE Mark expected to enable distribution and revenue.

Modular Medical (NASDAQ:MODD) launched digital tools for insulin pump training, developed with Relevate Health Games. The resources, not part of FDA-required training, aim to familiarize patients with Pivot tubeless patch pump before formal training. The tools include a virtual walkthrough and a module in the Level One diabetes game, downloaded over 53,000 times. The company is preparing for the full commercial launch of its Pivot pump.

Modular Medical, Inc. (MODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 25, 2026, Jeffrey Goldberg provided written notice to the chair of the nominating and governance committee (th

Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.

Modular Medical, Inc. (NASDAQ:MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to its Pivot tubeless patch pump for diabetes patients. The company believes this partnership will broaden patient access and validate its insulin delivery system. Modular Medical aims to simplify diabetes management with its innovative medical device.

Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Modular Medical (NASDAQ:MODD) said it is running a strategic pilot with IMO Health to build an EHR-based, terminology-powered algorithm that identifies diabetes patients likely to benefit from its Pivot insulin pump. The pilot will use clinician-guided phenotypes and IMO Health terminology value sets, supporting a planned Pivot commercial launch in Q4 2026.

Modular Medical, Inc. (Nasdaq: MODD) announced that its CEO, Jeb Besser, will present at Tribe Public's webinar "From FDA Wins to Scaling Manufacturing - What Investors Should Watch" on Friday, May 1, 2026. The event will focus on Modular Medical's newly FDA-cleared Pivot insulin patch pump, designed to make insulin delivery more accessible and affordable for the 4.8 million Americans with diabetes. Investors are encouraged to register to learn about the company's commercial and manufacturing timelines, as well as its strategy to target the large underserved market of individuals currently using multiple daily injections.